Could a treatment switch cut infection risk in MS patients?
NCT ID NCT06854094
First seen Mar 12, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This study looks at whether switching from anti-CD20 drugs (like ocrelizumab) to cladribine can improve immune function and lower infection risk in people with relapsing multiple sclerosis. About 70 participants will be followed for 2 years. The goal is to see if the switch helps stabilize antibody levels and reduce infections compared to staying on anti-CD20 therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ospedale Regionale di Lugano, Istituto di Neuroscienze Cliniche della Svizzera Italiana, Via Tesserete 46,
Lugano, Canton Ticino, 6903, Switzerland
Conditions
Explore the condition pages connected to this study.